Metastatic melanoma: results of 'classical' second-line treatment with cytotoxic chemotherapies

• Published in: The Journal of dermatological treatment Vol. 25; no. 5; pp. 396 - 400
• Main Authors: Perrin, Christophe, Pracht, Marc, Talour, Karen, Adamski, Henri, Cumin, Isabelle, Porneuf, Marc, Talarmin, Marie, Mesbah, Habiba, Audrain, Odile, Moignet, Aline, Lefeuvre-Plesse, Claudia, Lesimple, Thierry
• Format: Journal Article
• Language: English
• Published: Oslo Informa Healthcare USA on behalf of Informa UK Ltd 01.10.2014; Taylor & Francis
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Biological and medical sciences; chemotherapy; Dermatology; Female; Humans; Male; Medical sciences; melanoma; Melanoma - drug therapy; Melanoma - mortality; metastasis; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Pharmacology. Drug treatments; prognosis; Retrospective Studies; second-line; Skin Neoplasms - drug therapy; Skin Neoplasms - mortality; Skin, nail, hair, dermoskeleton; Survival Analysis; Treatment Failure; Treatment Outcome; Tumors; Tumors of the skin and soft tissue. Premalignant lesions; Young Adult; Chemotherapy; Treatment; Prognosis; second-line; Malignant melanoma; Advanced stage; Second line treatment; melanoma; Malignant tumor; Metastasis; Cancer; Result

Abstract Background: Metastatic melanoma is one of the most aggressive tumours, with a median survival that does not exceed 12 months. None of the cytotoxic first-line therapies have shown survival benefit in randomised clinical trials. Objective: To describe clinical benefit of second-line cytotoxi...